Cellceutix Begins Phase 2 Trial of Ulcerative Proctitis Drug Candidate Brilacidin

Cellceutix Begins Phase 2 Trial of Ulcerative Proctitis Drug Candidate Brilacidin
Cellceutix  recently began screening participants and administering therapy for its Phase 2 trial assessing the drug candidate Brilacidin for the treatment of ulcerative proctitis, a mild form of ulcerative colitis. The causes for the development of ulcerative proctitis and ulcerative proctosigmoiditis are not yet known, but the conditions are often initially treated with oral or rectal 5-aminosalicyclic acid or corticosteroids. However,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *